<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030194</url>
  </required_header>
  <id_info>
    <org_study_id>I 1574221</org_study_id>
    <nct_id>NCT05030194</nct_id>
  </id_info>
  <brief_title>Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Cigarette Smokers Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]</brief_title>
  <official_title>Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Cigarette Smokers Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To pilot test the appeal of non-tobacco oral nicotine products in cigarette smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the use, nicotine delivery, subjective response, and sensory appeal of&#xD;
      an oral nicotine product (ZYN) compared to electronic nicotine delivery systems (ENDS, Vuse&#xD;
      Alto) in cigarette smokers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nicotine boost</measure>
    <time_frame>up to week 4</time_frame>
    <description>will be measured as the post bout plasma nicotine concentration minus the pre-bout plasma nicotine concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sensory response</measure>
    <time_frame>up to 1 year</time_frame>
    <description>will be measured by a Questionnaire scored on a 0-100 visual analog scale with 0 (Not at all) to 100 (Extremely).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change is stress markers</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Saliva will be collected before and after product use of each product to establish plasma nicotine concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will use each product for up to a 30 minute interval But will also be permitted to stop use before the end of the 30-minute ad lib use period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Order 2 - Electronic Cigarettes and Oral Nicotine product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will use each prodcut for up to 30 minutes but will also be permitted to stop use before the end of the 30-minute ad lib use period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Cigarette</intervention_name>
    <description>Participants engage in 30 minutes of an oral nicotine product. In those 30 minutes the product can be used as much or as little as preferred.</description>
    <arm_group_label>Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes</arm_group_label>
    <arm_group_label>Order 2 - Electronic Cigarettes and Oral Nicotine product</arm_group_label>
    <other_name>Vuse Alto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Nicotine Pouch</intervention_name>
    <description>Participants will be instructed to place a 6mg nicotine pouch in their mouth between gum and lip for up to 30 minutes.</description>
    <arm_group_label>Order 1 - Oral Nicotine product - ZYN and Electronic Cigarettes</arm_group_label>
    <arm_group_label>Order 2 - Electronic Cigarettes and Oral Nicotine product</arm_group_label>
    <other_name>ZYN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current daily cigarette smoker as determined by:&#xD;
&#xD;
             a. Smokes &gt;5 cigarettes/day for &gt;1 year&#xD;
&#xD;
          -  Willingness to abstain from using cigarettes for 8-10 hours (overnight abstinence)&#xD;
             prior to study visits (verified by exhaled-air carbon monoxide &lt; 10ppm).&#xD;
&#xD;
          -  Self-report fair or better physical health.&#xD;
&#xD;
          -  Self-report fair or better mental health.&#xD;
&#xD;
          -  Participant must understand the investigational nature of this study and sign an&#xD;
             Independent Ethics Committee/Institutional Review Board approved written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently uses other tobacco or nicotine products (e.g., smokeless tobacco, ENDS) &gt; 2&#xD;
             days/week.&#xD;
&#xD;
          -  Self-report having active, untreated medical/psychiatric conditions History of serious&#xD;
             side effects from nicotine or from any nicotine replacement therapies.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Nursing female participants.&#xD;
&#xD;
          -  Vulnerable populations, such as cognitively impaired adults, individuals who are not&#xD;
             yet adults, pregnant women, and prisoners.&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements.&#xD;
&#xD;
          -  Any condition which in the Investigator's opinion deems the participant an unsuitable&#xD;
             candidate to receive study drug.&#xD;
&#xD;
          -  Previous use of either of the study products (ZYN or Vuse Alto).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Felicione, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Felicione, PhD</last_name>
    <phone>716-845-1300</phone>
    <phone_ext>7846</phone_ext>
    <email>Nicholas.Felicione@roswellpark.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Felicione</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

